AM
Andrew Hollman Meyer
Chief Business Officer

Andrew Hollman Meyer insider trades: Janux Therapeutics (JANX) stock sales

Chief Business Officer, Janux Therapeutics Last trade Jan 2, 2026 14 Form 4 filings
$236K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2024
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Andrew reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 2, 2026JANX↓ Sell$26K
Dec 1, 2025JANX↓ Sell$110K
Nov 14, 2025JANX↓ Sell$100K
Oct 28, 2025JANX↓ Sell$501K
May 1, 2025JANX↓ Sell$107K
Apr 21, 2025JANX↓ Sell$100K
Mar 3, 2025JANX↓ Sell$107K
Feb 3, 2025JANX↓ Sell$141K
Jan 2, 2025JANX↓ Sell$732K
Sep 27, 2024JANX↓ Sell$2.3M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other JANX insiders

Open-market trades in the last 12 months

About Andrew Hollman Meyer's insider trades

Andrew Hollman Meyer is Chief Business Officer at Janux Therapeutics (JANX). Since Sep 27, 2024, Andrew has reported no open-market purchases and 10 sales worth $4.2M on SEC Form 4. In the last 12 months: 3 sales ($236K).

Their filings also include option exercises (9 filings), grants and awards (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every JANX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.